The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, vTv Therapeutics's share price is €30.20.
vTv Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €2.18. Hence, vTv Therapeutics's PS Ratio for today is 13.87.
The historical rank and industry rank for vTv Therapeutics's PS Ratio or its related term are showing as below:
FRA:5VT0'
s PS Ratio Range Over the Past 10 Years
Min: 1.5 Med: 56.47 Max: 13200
Current: 13.97
During the past 13 years, vTv Therapeutics's highest PS Ratio was 13200.00. The lowest was 1.50. And the median was 56.47.
FRA:5VT0's PS Ratio is ranked worse than 58.52% of 933
companies
in the Biotechnology industry
Industry Median: 9.64
vs FRA:5VT0: 13.97
During the past 13 years, vTv Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 151.70% per year. The lowest was -60.00% per year. And the median was -1.40% per year.
Back to Basics: PS Ratio
vTv Therapeutics (FRA:5VT0) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
vTv Therapeutics PS Ratio Related Terms
vTv Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for vTv Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, vTv Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
vTv Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, vTv Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where vTv Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
vTv Therapeutics's Share Price of today is €30.20. vTv Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.18.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
vTv Therapeutics (FRA:5VT0) has a PS Ratio of 13.87 as of Jul. 04, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on vTv Therapeutics and its competitors. This is 75% below median its historical median of 56.47. Over the past decade, vTv Therapeutics' PS Ratio has ranged from 1.50 to 13,200.00. According to the industry distribution chart, vTv Therapeutics ranks #546 out of 933 companies in the Biotechnology industry, placing it in the top 58.5%.
Is vTv Therapeutics' PS Ratio too high?
vTv Therapeutics' current PS Ratio of 13.87 is 75% below median its 10-year median of 56.47. Over the past 10 years, this metric has ranged from a low of 1.50 to a high of 13,200.00. The Biotechnology industry median PS Ratio is 9.64. vTv Therapeutics' value of 13.87 is 43.9% above this industry median. Based on the distribution chart, vTv Therapeutics ranks #546 out of 933 companies in the Biotechnology industry, which is below the industry midpoint. Overall, vTv Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does vTv Therapeutics' PS Ratio compare to SMNR and CNTB?
According to the Biotechnology industry distribution chart, vTv Therapeutics ranks #546 out of 933 companies for PS Ratio. This places vTv Therapeutics in the lower half of its industry. The industry median PS Ratio is 9.64. vTv Therapeutics' value of 13.87 is 43.9% above this benchmark. Historically, vTv Therapeutics' own PS Ratio has ranged from 1.50 to 13,200.00 over the past decade. While the company's 10-year median is 56.47 vs. the industry median of 9.64, vTv Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.64, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. vTv Therapeutics's current PS Ratio of 13.87 is 43.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on vTv Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. vTv Therapeutics's current PS Ratio is 13.87, which is 75% below median its own 10-year median of 56.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is vTv Therapeutics stock overvalued right now?
vTv Therapeutics (FRA:5VT0) has a current PS Ratio of 13.87. The stock's GF Value™ is €6,725.03, compared to a current price of €30.20 — trading 99.6% below its estimated fair value. The current PS Ratio is 13.87, which is 75% below median its 10-year median of 56.47 and 43.9% above the Biotechnology industry median of 9.64. vTv Therapeutics' overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For vTv Therapeutics (FRA:5VT0), the current PS Ratio is 13.87 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is vTv Therapeutics (FRA:5VT0) Overvalued in 2026?
Based on GuruFocus' analysis, vTv Therapeutics stock appears to be undervalued.
The current stock price of €30.20 is trading 99.6% below its estimated GF Value™ of €6,725.03.
Key valuation signals for FRA:5VT0:
PS Ratio: 13.87 (75% below median its 10-year median of 56.47)
GF Value™: €6,725.03 vs. price of €30.20 (99.6% below fair value)
Industry Position: 43.9% above the Biotechnology median (#546 of 933)
No single metric tells the full story. See the FRA:5VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
35GF Score
Get the complete analysis for FRA:5VT0
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5VT0 has been successfully added to your 
